VANCOUVER, British Columbia, Jan. 20, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions, today announced that the Company will ring the closing bell at the Nasdaq Stock Market (Nasdaq) on Thursday, January 22, 2026 in New York City. Adam Rogers, MD, Chairman and Interim Chief Exe ...

Core Viewpoint - NervGen Pharma Corp. has received approval for its common shares to be listed on Nasdaq, marking a significant milestone in its development as a biopharmaceutical company focused on neuroreparative therapeutics for spinal cord injury and other neurological conditions [1] Company Overview - NervGen Pharma is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics aimed at transforming the lives of individuals with spinal cord injury (SCI) [2] - The lead therapeutic candidate, NVG-291, is a subcutaneously administered neuroreparative peptide that has shown durable improvements in function, independence, and quality of life in chronic SCI patients [2] - NVG-291 has received Fast Track designation from the FDA and Orphan Drug designation from the European Medicines Agency for the treatment of SCI [2] Recent Developments - The listing on Nasdaq is expected to enhance market visibility, improve liquidity, and broaden the shareholder base, ultimately driving long-term shareholder value as the company advances NVG-291 [1] - Recent Phase 1b/2a CONNECT SCI Study data revealed unprecedented durable improvements in function and quality of life for individuals with chronic SCI, with significant enhancements in upper-limb corticospinal signaling [1] - The company plans to conduct a U.S. FDA End-of-Phase 2 meeting in early 2026 to discuss the development and registration pathway for NVG-291 [1]

Core Viewpoint - NervGen Pharma Corp. is amending the exercise price of its 2022 Warrants from US$1.75 to the Canadian equivalent of C$2.44 to align with its functional currency and simplify accounting treatment, while all other terms remain unchanged [1] Company Overview - NervGen Pharma Corp. is a clinical-stage biopharmaceutical company focused on developing neuroreparative therapeutics for spinal cord injury and other neurological disorders [1][3] - The company is evaluating its lead candidate, NVG-291, in the Phase 1b/2a CONNECT SCI Study for spinal cord injury [3] Product Information - NVG-291 is a first- and potential best-in-class therapeutic peptide that enables the nervous system to repair itself, with exclusive worldwide rights held by NervGen [2] - The technology for NVG-291 is licensed from Case Western Reserve University, based on studies showing its preclinical efficacy in promoting neurorepair and functional improvement in spinal cord injury models [2] - NVG-291 has received Fast Track designation from the FDA and Orphan Designation from the EMA for spinal cord injury [2]

NervGen Pharma Reports Second Quarter Financial Results and Provides Letter to ShareholdersAugust 26, 2025 7:30 AM EDT | Source: NervGen Pharma Corp.Announced unprecedented Phase 1b/2a topline results in chronic spinal cord injury NVG-291 is the first pharmacologic candidate to demonstrate statistically significant improvement in corticospinal connectivity with clinically meaningful functional gainsOngoing comprehensive analysis of NVG-291's efficacy profile will support upcoming regulatory di ...

NervGen Pharma's NVG-291-R Demonstrates Significant Functional Recovery in Department of Defense-Sponsored Preclinical Models of Traumatic Hearing Loss and Peripheral Nerve Injury August 21, 2025 7:30 AM EDT | Source: NervGen Pharma Corp. Vancouver, British Columbia--(Newsfile Corp. - August 21, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other neurologic disorders, toda ...